Table 1:
Demographic and clinical features of SLE patients (n=1827) at enrolment.
| Sex (%) | Female | 1623 (88.8) |
| Male | 204 (11.2) | |
| Age (years) (mean ± SD) | 35.1 ± 13.3 | |
| Race/Ethnicity (%) | Caucasian | 891 (48.8) |
| African | 307 (16.8) | |
| Hispanic | 282 (15.4) | |
| Asian | 275 (15.1) | |
| Other | 72 (3.9) | |
| Single/Married/Other (%) | 819 (44.9)/766 (42.0)/238 (13.1) | |
| Post-secondary education (%) | 1065 (61.9) | |
| Disease duration (months) (mean ± SD) | 5.6 ± 4.2 | |
| Number of ACR criteria (mean ± SD) | 4.9 ± 1.1 | |
| ACR manifestations (%) | Malar rash | 660 (36.1) |
| Discoid rash | 227 (12.4) | |
| Photosensitivity | 653 (35.7) | |
| Oral/nasal ulcers | 678 (37.1) | |
| Serositis | 502 (27.5) | |
| Arthritis | 1368 (74.9) | |
| Renal disorder | 510 (27.9) | |
| Neurological disorder | 88 (4.8) | |
| Hematologic disorder | 1130 (61.9) | |
| Immunologic disorder | 1393 (76.2) | |
| Antinuclear antibody | 1732 (94.8) | |
| SLEDAI-2K score (mean ± SD) | 5.3 ± 5.4 | |
| *SLICC/ACR damage index score (mean ± SD) | 0.32 ± 0.74 | |
| Medications (%) | Corticosteroids | 1285 (70.3) |
| Antimalarials | 1231 (67.4) | |
| Immunosuppressants | 732 (40.1) | |
| ASA | 261 (14.3) | |
| Antidepressants | 184 (10.1) | |
| Warfarin | 99 (5.4) | |
| Anticonvulsants | 80 (4.4) | |
| Antipsychotics | 12 (0.7) | |
| Autoantibody positivity N (%) | Lupus anticoagulant | 241/1174 (20.5) |
| Anti-cardiolipin | 138/1142 (12.1) | |
| Anti-Beta2 glycoprotein-I | 163/1142 (14.3) | |
| Anti-ribosomal P Anti-NR2 |
112/1136 (9.9) 130/1064 (12.2) |
*
SLICC/ACR damage index not available in 1058 patients at enrollment visit when disease duration < 6 months